Sarah Joanne Williams sold $1,504 of ANTX
Principal Accounting Officer at AN2 Therapeutics, Inc.. 272 shares at an average of $5.53, traded Sep 1, 2026, filed Sep 4, 2026.
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- 0Share of holdings soldSold 0.4% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-383697, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | SOpen-market sale Common Stock | -272 | $5.53 | $1,504 | 66,311 | 38 d ago |
Related signals
Other insiders at AN2 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $6,675 1,108 shares | -0% | |
| 13Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $97k 16,119 shares | -3% | |
| 21Weak | ANTXbuy AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $12k 2,098 shares | +24% | |
| 23Weak | AN2 Therapeutics, Inc. | Stephen David Prior Chief Strategy Officer | $872 765 shares | -1% | |
| 23Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $3,214 2,819 shares | -2% | |
| 24Weak | ANTXsell AN2 Therapeutics, Inc. | Braden Michael Leonard owner | $218k 200,000 shares | -6% | |
| 51Moderate | AN2 Therapeutics, Inc. | Eric Easom Chief Executive Officer | $11k 10,000 shares | +4% | |
| 47Moderate | ANTXsell AN2 Therapeutics, Inc. | Braden Michael Leonard owner | $2.9M 2,532,000 shares | -44% | |
| 39Weak | AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $10k 8,610 shares | - | |
| 30Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $13k 9,663 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.